Wendys Co (WEN) Stock Price Today
Aura AI Summary
Key Stats
- $1.44BMarket Cap
- -Volume
- Consumer CyclicalSector
- $11.3352W High
- $6.1752W Low
- -Typical Hold Time
- $5.26BEnterprise Value
- 7.41%Div Yield
- -Trading Activity
Track Wendys Co (WEN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Wendys Co has traded between a low of $6.17 and a high of $11.33, highlighting its annual price range. Buy and sell Wendys Co shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Most Recent News
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.